Author:
Shangase Nosipho,Kufa Tendesayi
Reference10 articles.
1. Update of recommendations on first- and second-line antiretroviral regimens,2019
2. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial;Aboud;Lancet Infect Dis,2019
3. Adaption of an ongoing clinical trial to quickly respond to gaps in changing international recommendations: the experience of D(2)EFT;Papot;HIV Res Clin Pract,2022
4. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial
5. Recycling tenofovir in second-line antiretroviral treatment with dolutegravir: outcomes and viral load trajectories to 72 weeks;Keene;J Acquir Immune Defic Syndr,2023